Health Economics Research Group, Brunel University, Uxbridge, Middlesex, UK.
Value Health. 2013 Jan-Feb;16(1):202-10. doi: 10.1016/j.jval.2012.10.010.
Quality-adjusted life-years (QALYs) are widely used as an outcome for the economic evaluation of health interventions. However, preference-based measures used to obtain health-related utility values to produce QALY estimates are not always included in key clinical studies. Furthermore, organizations responsible for reviewing or producing health technology assessments (HTAs) may have preferred instruments for obtaining utility estimates for QALY calculations. Where data using a preference-based measure or the preferred instrument have not been collected, it may be possible to "map" or "crosswalk" from other measures of health outcomes. The aims of this study were 1) to provide an overview of how mapping is currently used as reported in the published literature and in an HTA policy-making context, specifically at the National Institute for Health and Clinical Excellence in the United Kingdom, and 2) to comment on best current practice on the use of mapping for HTA more generally. The review of the National Institute for Health and Clinical Excellence guidance found that mapping has been used since first established but that reporting of the models used to map has been poor. Recommendations for mapping in HTA include an explicit consideration of the generalizability of the mapping function to the target sample, reporting of standard econometric and statistical tests including the degree of error in the mapping model across subsets of the range of utility values, and validation of the model(s). Mapping can provide a route for linking outcomes data collected in a trial or observational study to the specific preferred instrument for obtaining utility values. In most cases, however, it is still advantageous to directly collect data by using the preferred utility-based instrument and mapping should usually be viewed as a "second-best" solution.
质量调整生命年 (QALY) 被广泛用作健康干预经济评估的结果。然而,用于生成 QALY 估计值的获得健康相关效用值的基于偏好的测量方法并不总是包含在关键临床研究中。此外,负责审查或制作卫生技术评估 (HTA) 的组织可能有首选工具来获得用于 QALY 计算的效用估计值。在未收集使用基于偏好的测量方法或首选工具的数据的情况下,可能可以从其他健康结果测量中“映射”或“交叉”。本研究的目的是 1) 提供对当前在已发表文献和 HTA 决策制定背景下报告的映射方法的概述,特别是在英国国家卫生与临床卓越研究所,以及 2) 评论一般 HTA 中使用映射的最佳当前实践。对国家卫生与临床卓越研究所指导意见的审查发现,自成立以来一直使用映射,但映射所使用的模型报告不佳。HTA 中映射的建议包括明确考虑映射函数对目标样本的可推广性,报告标准计量经济学和统计检验,包括映射模型在效用值范围内的子集之间的误差程度,以及验证模型。映射可以提供一种将试验或观察性研究中收集的结果数据与获得效用值的特定首选工具联系起来的途径。然而,在大多数情况下,直接使用首选基于效用的工具收集数据仍然具有优势,映射通常应被视为“第二最佳”解决方案。